The world’s first PSMA-targeted bispecific drug conjugate CBP-1018 makes a fantastic appearance at the 2023 ESMO

Coherent Biopharma announced that clinical data will be presented in the form of a poster at the 2023 European Society for Medical Oncology (ESMO) annual meeting to be held from October 20th to 24th, 2023. The details are as follows:


For more information, please visit the official website of the conference.:

Poster Presentation 

Selected project: CBP-1018 Poster

ID: #5998

Abstract title: CBP-1018, a Bi-Ligand-Drug Conjugate treated in Patients with Advanced Solid Tumors: A Phase 1, Multi-Center, Open-Label, Dose-Escalation and Dose expansion Study

About CBP-1018

CBP-1018 is the first PSMA and FRα-targeted bispecific drug conjugate developed based on Coherent Biopharma’s Bi-XDC technology platform, and also the first dual-ligand PSMA-targeted drug conjugate developed in the world.

In preclinical studies, CBP-1018 has shown excellent anti-tumor effects on various solid tumors such as prostate cancer, renal cell carcinoma, lung adenocarcinoma, and squamous cell carcinoma. CBP-1018 has advantages such as stronger target specificity, greater stability in human plasma, higher water solubility, and faster clearance.

The CBP-1018 phase Ia clinical trial demonstrated good safety and clear clinical efficacy, and is currently in the Ib dose-expansion stage.